Is Buying Stock In Amryt Pharma plc (AMYT) A Good Move Today?

0
1

Amryt Pharma plc (NASDAQ:AMYT) remained unchanged to close Tuesday at $14.60 after subtracting $0.0 on the day. The 5-day average trading volume is 1,280,400 shares of the company’s common stock. It has gained $14.74 in the past week and touched a new high 1 time within the past 5 days. An average of 1,394,645 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 588,228.

AMYT’s 1-month performance is 104.48% or $7.40 on its low of $7.00 reached on 01/06/23. The company’s shares have touched a 52-week low of $5.61 and high of $14.77, with the stock’s rally to the 52-week high happening on 01/13/23. YTD, AMYT has achieved 100.00% or $7.30 and has reached a new high 5 times. However, the current price is down -1.15% from the 52-week high price.


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored


Valuation Metrics

Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 2.54 while the price-to-book (PB) in the most recent quarter is 2.89, with the price to cash flow ratio at 5.80.

Amryt Pharma plc’s quick ratio for the period ended September 29 was 0.90, with the current ratio over the same period at 1.60. As well, the company’s long term debt to equity for the quarter ending September 29 was 0.65, while the total debt to equity was 0.66.. In terms of profitability, the gross margin trailing 12 months is 47.90%. The firm’s gross profit as reported stood at $116.42 million against revenue of $222.54 million.

Earnings Surprise

For the quarterly period ending September 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Analysts expected AMYT to announce -$0.05 per share in earnings in its latest quarter, but it posted -$0.06, representing a -20.00% surprise. EBITDA for the quarter stood at more than $9.58 million. AMYT stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 412.6 million, with total debt at $212.79 million.

Let’s look briefly at Amryt Pharma plc (AMYT) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 89.66% to suggest the stock is trending Overbought, with historical volatility in this time period at 8.74%.

The stock’s 5-day moving average is $14.64, reflecting a -0.68% or -$0.10 change from its current price. AMYT is currently trading +104.20% above its 20-day SMA, +96.50% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +108.57% and SMA200 by+86.22%.

Stochastic %K and %D was 98.11% and 98.40% and the average true range (ATR) pointed at 0.44. The RSI (14) points at 88.23%, while the 14-day stochastic is at 97.81% with the period’s ATR at 0.48. The stock’s 9-day MACD Oscillator is pointing at -0.05 and 1.58 on the 14-day charts.

Analyst Ratings

Analysts offering their rating for AMYT stock have a consensus rating for the stock as Hold. Currently, 0 brokerage advisors rate AMYT as a “sell,”, while 6 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 1 have offered a “buy” rating.

What is AMYT’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $14.50 and a high of $38.00, with their median price target at $17.00. Looking at these predictions, the average price target given by analysts is for Amryt Pharma plc (AMYT) stock is $20.54.

LEAVE A REPLY

Please enter your comment!
Please enter your name here